[PERSON]  
1 Research Center in Sport Sciences, Health and Human Development, CIDESD, 6201-001 Covilha, Portugal, [EMAIL_ADDRESS]  
2 Associado de Investigacao de Guadalos de Sopurte em Oncologia (AICSO), 4410-406 Vila Nova de Gaia, Portugal, [EMAIL_ADDRESS] (A.A.); [EMAIL_ADDRESS] (A.J.) [PERSON]  
1 Research Center in Sport Sciences, Health and Human Development, CIDESD, 6201-001 Covilha, Portugal, [EMAIL_ADDRESS]  
2 Associado de Investigacao de Investigacao de Guadalos de Sopurte em Oncologia (AICSO), 4410-406 Vila Nova de Gaia, Portugal, [EMAIL_ADDRESS] (A.A.); [EMAIL_ADDRESS] (A.J.) [PERSON]  
1 Research Center in Sport Sciences, Health and Human Development, CIDESD, 6201-001 Covilha, Portugal, [EMAIL_ADDRESS]  
2 Associado de Investigacao de Guadalos de Sopurte em Oncologia (AICSO), 4410-406 Vila Nova de Gaia, Portugal, [EMAIL_ADDRESS] (A.A.); [EMAIL_ADDRESS] (A.J.) [PERSON]  
1 Research Center in Sport Sciences, Health and Human Development, CIDESD, 6201-001 Covilha, Portugal, [EMAIL_ADDRESS]  
2 Associado de Investigacao de Investigacao de Guadalos de Sopurte em Oncologia (AICSO), 4410-406 Vila Nova de Gaia, Portugal, [EMAIL_ADDRESS] (A.A.); anaisbesioaquim@gmail. population of survivors, patients living with and beyond BC face a multiple short and long-term treatment-related side effects [3; 4]. Cardiotoxicity has been raised as a major concern in clinical practice, that may restrict or delay treatment options [5], contributing to long-term cardiovascular morbidity and mortality among women with history of BC [6; 7]. Despite playing a crucial role for BC treatment, the exposure to drugs such as anthracyclines or to the anti-HER2 newer molecular targeted therapies such as trastuzumab are clinically associated with cardiotoxicity [8], usually manifested by, but not limited to, left ventricular dysfunction to overt heart failure [5; 9]. Currently, recommendations for monitoring treatment-related cardiotoxicity entail clinical examination and serial echocardiographic assessments [10]. Resting left ventricular ejection fraction (LVEF) is the standard marker for reporting anticancer therapy-related cardiotoxicity [10]. Cardiotoxicity is defined by a decrease in left ventricular ejection fraction (LVEF) of \(>\)10% to a value below the lower limit of normal [9; 10]. However, the determination of LVEF has substantial technical limitations and is considered a poor sensitivity parameter to detect cardiotoxicity at an early stage [10]. As such, an integrated approach that includes the assessment of other echocardiographic outcomes (diastolic function and strain imaging) and circulating biomarkers has been recommended [10; 11]. Besides the importance of screening and detection, the implementation of preventive strategies to optimize cardiovascular health of BC patients treated with cardiotoxic therapies is also an important component to be considered. Exercise training is a core component of cardiac rehabilitation and has a major role in primary and secondary prevention of cardiovascular disease [12]. In oncology, exercise has been widely accepted to be a safe and tolerable approach, during or after treatment, playing a beneficial effect on a wide range of physiological and subject-reported outcomes [13; 14; 15]. Furthermore, exercise has been associated with a substantial decrease in the risk of cardiovascular disease [16; 17] and, thus, there has been an increasing interest in exploring the role of exercise for mitigating cancer treatment-related cardiotoxicity. This systematic review aims to analyze the effects of exercise, performed during anthracycline or trastuzumab-containing therapy (TC-T), on conventional cardiac function outcomes and circulating biomarkers among women with BC.